JSKN016 injection

DRUG2 trials

Sponsors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Conditions

Advanced Malignant Solid TumorTriple Negative Breast Cancer

Phase 1

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

RecruitingNCT06592417

Jiangsu Alphamab Biopharmaceuticals Co., LtdAdvanced Malignant Solid Tumor

Start: 2024-04-30End: 2026-12-31Target: 140Updated: 2024-09-19

Phase 3

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

RecruitingNCT07533123

Jiangsu Alphamab Biopharmaceuticals Co., LtdTriple Negative Breast Cancer

Start: 2026-03-17End: 2030-03-17Target: 364Updated: 2026-04-16

Related Papers

Abstract PS1-09-05: Jskn016, a first-in-class anti-TROP2/HER3 bispecific antibody drug conjugate (ADC) in patients with HER2-negative locally advanced or metastatic breast cancer: results from a phase I study

Clinical Cancer Research2026-02-17

First-in-human study of JSKN016, a bispecific anti-TROP2/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results.

Journal of Clinical Oncology2025-05-284 citations